Genelux Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GNLX research report →
About the company
Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor malignancies. Its leading experimental drug, Olvi-Vec, is a proprietary, engineered vaccinia virus strain being developed to address ovarian cancer and non-small cell lung cancer. The company is also advancing V2ACT Immunotherapy for pancreatic cancer, alongside V-VET1 for the treatment of both hematologic and solid cancers.
- CEO
- Thomas D. Zindrick
- IPO
- 2023
- Employees
- 24
- HQ
- Westlake Village, CA, US
Price Chart
- Market Cap
- $112.47M
- P/E
- -3.40
- P/S
- 14059.32
- P/B
- 4.24
- EV/EBITDA
- -3.30
- Div Yield
- 0.00%
- Gross Margin
- -3550.00%
- Op Margin
- -422037.50%
- Net Margin
- -397225.00%
- ROE
- -165.18%
- ROIC
- -132.84%
- Revenue
- $8.00K · 0.00%
- Net Income
- $-32,145,000 · -7.62%
- EPS
- $-0.86 · 9.47%
- Op Income
- $-33,214,000
- FCF YoY
- -22.01%
- 52W High
- $8.54
- 52W Low
- $2.29
- 50D MA
- $2.89
- 200D MA
- $3.70
- Beta
- 0.55
- Avg Volume
- 190.96K
Get TickerSpark's AI analysis on GNLX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 1, 26 | Smither John W | sell | 12,000 |
| Jun 16, 26 | Pulisic Matthew | other | 278,906 |
| Jun 16, 26 | Groen Eric | other | 233,957 |
| Jun 16, 26 | Cappello Joseph | other | 174,841 |
| Jun 16, 26 | Tyree James L | other | 28,409 |
| Jun 16, 26 | Tyree James L | other | 31,566 |
| Jun 16, 26 | Zindrick Thomas | other | 730,601 |
| Jun 16, 26 | Thomas John | other | 28,409 |
| Jun 16, 26 | Thomas John | other | 31,566 |
| Jun 16, 26 | Mirabelli Mary | other | 28,409 |
Our GNLX coverage
Recent articles, reports, and earnings notes.
No research on GNLX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate GNLX report →Similar companies
Peers in the same neighborhood.